-
Novel Therapies for Neurofibromatosis Type 1-Associated Inoperable Plexiform Neurofibromas: A Systematic Literature Review
Mar 10, 2025, 14:00 PM -
Considerations for Health Economic Modeling in Phenylketonuria (PKU): Insights From a Modified Delphi Panel
Mar 10, 2025, 14:00 PM -
Optimized Treatment Sequences for ALK+ Stage IV NSCLC: Cost-Effectiveness Analysis From RCT data and Real-World Evidence
Mar 10, 2025, 14:00 PM -
Exploring the Impact of Exercise Variability of Mental Health: Results From the 2024 US National Health and Wellness Survey
Mar 10, 2025, 14:00 PM -
Characteristics of Patients With Minimal Residual Disease (MRD) Testing for Solid Tumors in a United States Population With Commercial or Medicare Advantage (MA) Insurance
Mar 10, 2025, 14:00 PM -
Assessing Prescribing Trends for Select Glucagon-Like Peptide Receptor Agonists (GLP-1s) by Patient Demographics, Providers, and Indication
Mar 10, 2025, 14:00 PM -
How Disease Modifying Therapy Utilization In Multiple Sclerosis Is Influenced by Insurance and Out-Of-Pocket Cost in US Adults: A Summary Of Recent Literature
Mar 10, 2025, 14:00 PM -
Integrating Next Generation Sequencing, EHR, and Claims Data to Extend Follow-Up in a Real-World Advanced Lung Adenocarcinoma Biomarker-Treatment Landscape
Mar 10, 2025, 14:00 PM -
Comparison of Selective Serotonin Reuptake Inhibitors and USA Food and Drug Administration-Approved Serotonin-Norepinephrine Reuptake Inhibitors Treatments for Fibromyalgia: A Systematic Review and Network Meta-Analysis
Mar 10, 2025, 14:00 PM -
Payer Archetypes and Decision-Making in the United States (US): A framework for Generalised Cost-Effectiveness Analysis (GCEA) Value Elements to Optimize Patient Access and Equity
Mar 10, 2025, 14:00 PM -
Presenteeism in Employees with Chronic Conditions: An Analysis Using Linked Claims and Self-Reported Employee Health Risk Assessment Data
Mar 10, 2025, 14:00 PM -
Clinical Characteristics and Healthcare Resource Utilization Among Patients Initiating Semaglutide 2.4mg Versus Those Not Treated With Anti-Obesity Medications
Mar 10, 2025, 14:00 PM -
A Conceptual Model of Multiple Myeloma Symptoms and Impacts, and A Characterization of Pain Among Patients Living With Relapsed/Refractory Multiple Myeloma
Mar 10, 2025, 14:00 PM -
Moving Beyond Partitioned Survival Models in Oncology Submissions: Incorporation of Canada's Drug Agency Guidance on Model Structure
Mar 10, 2025, 14:00 PM -
Global, Regional, and National Burdens of Type 1 and Type 2 Diabetes Mellitus in Adolescents from 1990 to 2021, with Forecasts to 2030: A Systematic Analysis of the Global Burden of Disease Study 2021
Mar 10, 2025, 14:00 PM -
Direct Costs of Pneumococcal Disease in the United States - A Targeted Literature Review
Mar 10, 2025, 14:00 PM -
Estimation of Utilities for Patients with Metastatic Breast Cancer Using Vignette in Japan
Mar 10, 2025, 14:00 PM -
Racial Disparities in the Burden of Illness Among Adults with Prostate Cancer in the United States
Mar 10, 2025, 14:00 PM -
Healthcare Resource Utilization Associated With Myotonic Dystrophy Type 1 With Complex Care Needs: Results From the Real-World IMPaCT Study
Mar 10, 2025, 14:00 PM -
Quality-Adjusted Life Year (QALY) Results From a Cost-Effectiveness Model for Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Relapsed/Refractory Multiple Myeloma (RRMM)
Mar 10, 2025, 14:00 PM
